PlayBall10 schreef op 14 april 2018 10:24:
Aescap 2.0 passed 5% threshold in biotech ProQR
Yesterday evening Aescap 2.0 filed with the SEC that it has crossed the 5% shareholding threshold and currently owns 5.6% of the Nasdaq listed Dutch biotech company ProQR, based in Leiden.
ProQR was founded in 2012 and went public on Nasdaq raising $ 98M in September 2014. It is applying technologies, called RNA therapy, with the aim to address inherited diseases that are caused by a genetic defect. The company is developing treatments for devastating eye and skin diseases as well as the lung disease cystic fibrosis.
The CEO of ProQR, Daniel de Boer, will present at the Aescap 2.0 annual meeting on May 15.
Looking forward to report to you again early May.
Best regards on behalf of the Aescap team,
Aescap Medical Investments B.V.
Patrick J. H. Krol
Fund Manager Aescap 2.0